UNASSIGNED: @entity1893 is the fourth most common @entity5 in @entity1 , has an even higher incidence in adolescents, and is primarily represented by only a few histologic subtypes. Dramatic progress has been achieved, with survival rates exceeding 80%, in large part because of a better understanding of the biology of the different subtypes and national and international collaborations. Most @entity1 with @entity2109 and diffuse large @entity1892 are cured with short intensive pulse chemotherapy containing @entity786 , @entity2592 , and high-dose @entity1499 . The benefit of the addition of rituximab has not been established except in the case of primary mediastinal @entity1892 . @entity981 is treated with intensive, semi-continuous, @entity1778 -derived protocols. Relapses in @entity1892 are rare and infrequently curable, even with intensive approaches. Event-free survival rates of approximately 75% have been achieved in @entity2108 with various regimens that generally include a short intensive B-like regimen. Immunity seems to play an important role in prognosis and needs further exploration to determine its therapeutic application. @entity7041 inhibitor therapeutic approaches are currently under investigation. For all @entity706 , the intensity of induction/consolidation therapy correlates with acute @entity137 , but because of low cumulative doses of @entity8253 and alkylating agents, minimal or no long-term @entity137 is expected. Challenges that remain include defining the value of prognostic factors, such as early response on positron emission tomography/computed tomography and minimal disseminated and @entity66 , using new biologic technologies to improve risk stratification, and developing innovative therapies, both in the first-line setting and for relapse.

XXXX in @entity1 and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead.

@entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity7041 :: ('238', 'Gene') :: ['ALK'] @entity981 :: ('MESH:D054198', 'Disease') :: ['Lymphoblastic lymphoma'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease'] @entity706 :: ('MESH:D008223', 'Disease') :: ['pediatric lymphomas'] @entity8253 :: ('MESH:D018943', 'Chemical') :: ['anthracyclines'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity2109 :: ('MESH:D002051', 'Disease') :: ['Burkitt lymphoma'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['B-cell lymphoma', 'B-cell and lymphoblastic lymphomas'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['longer leukemia'] @entity2108 :: ('MESH:D017728', 'Disease') :: ['anaplastic large-cell lymphomas'] @entity1893 :: ('MESH:D008228', 'Disease') :: ['Non-Hodgkin lymphoma'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']
@entity1893 :: (MESH:D008228,Disease) :: ['Non-Hodgkin Lymphoma']
